Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies Luke E. Taylor, Amy L. Swerdfeger, Guy D. Eslick (Not an EpiVax publication) Highlights • Five cohort studies involving 1,256,407 children and five case-control studies involving 9920 children were included in this analysis. • There was no relationship between vaccination and autism (OR: 0.99; 95% CI: 0.92 to ...

EpiVax will be in Tokyo Japan from September 14th-20th, 2014 hosting our semiannual immunogenicity seminar and meeting with collaborators. The Westin Immunogenicity Seminar is scheduled for September 17th, 2014. The purpose of this seminar is to bridge the gap between recent academic research on Tregs, Tregitopes and protein drug development (immunogenicity, deimmunization and tolerance induction). Links PDF Agenda Last year’s event ...

APRIL 24, 2014 EpiVax CEO/CSO, Dr. Annie De Groot MD, will be one of the featured speakers during next week’s 66th Annual Clinical Laboratory Science Convention. The event is scheduled for April 29 through May 1 at the Rhode Island Convention Center in Providence. Dr. De Groot will speak on Tuesday, April 29 during a workshop on ...

Providence, R.I. – April 18, 2014 – Researchers from the University of Rhode Island and EpiVax, Inc. are championing a recent breakthrough in the laboratory with the hopes it could lead to a vaccine against the pathogen responsible for stomach cancer and other ailments. The results are published today in the Public Library of Science One ...

Platine ​and ​EpiVax are ​co-organizing ​their ​2nd ​seminar on Immunogenicity and Tolerance on October 24th, 2016. Click this link to register This meeting will focus on the determinants of immunogenicity – a key feature of effective vaccines and a key barrier to success in the clinic for protein therapeutics. Conversely, tolerance induction is a key feature of successful protein therapeutics, while ...

IcoVax Update: The publications from our “ICoVax 2013” pre-conference have now been published. The full content of the supplement can be found at this link. The link to the supplement is permanently accessible. We hope to see you at the next event! ICoVax description: The annual Vaccine & ISV Annual Global Congress, co-organized by the Vaccine journal and the International ...

From CIDRAP: Stealth Virus Moves in on Malaysia. This is the first case reported outside of China/Hong Kong; more are expected. The case fatality rate is currently at 24%. Health officials announced an H7N9 avian flu infection in Malaysia today, the first case detected outside of China, along with eight other newly confirmed cases—one in Hong ...

Avian Flu Concerns Shutter Poultry Markets 28 January 2014 4:15 pm 0 Comments M M (Padmanaba01)/Wikimedia CommonsFlu source? A poultry market in China. WASHINGTON, D.C.—With human cases of H7N9 avian influenza piling up, Chinese authorities have ordered the closure of live poultry markets in three eastern cities in a bid to stem transmission of the virus. So far, the Chinese ...

New research, same mission: ‘improve human health’ EPI CENTER: EpiVax founder and CEO Anne S. De Groot described herself as a “physician to make products that help human health everywhere.” PBN PHOTO/MICHAEL PERSSON By Harold Ambler Contributing Writer 1/13/14 If “immunoinformatics” ever becomes a household word, the team at Providence’s EpiVax Inc., led by CEO Dr. Anne S. De ...

Add two previous reports of the low immunogenicity of H7N9 HA, one from NovaVax, stating that their unadjuvanted vaccine is only 6-16% effective and Novartis – showing only 6% seroconversion for their unadjuvanted HA vaccine) to this report – and you have a slam dunk – three independent verifications that our tools accurately predict vaccine ...

Why work at EpiVax? Members of the EpiVax team strive to see beyond the horizon, desiring to be part of an effort that is bigger than themselves by contributing to improving human health by moving science forward.  In the long term, we aim to leave behind a legacy for the next generation, and we therefore continually ...

Date: Sun 8 Dec 2013 Story communicated by and reposted from: ProMED-mail South China Morning Post 19 people who came into contact with Hong Kong’s 2nd H7N9 flu patient are being kept in isolation in a hospital and at a holiday camp. They include 13 Tuen Mun Hospital patients who were being cared for in beds close to the 80-year-old man when ...

Seven RI Companies Receive $314,930 in SBIR Phase I Matching Grants Published on December 5, 2013 Seven Rhode Island companies are the first recipients of the Innovate Rhode Island Small Business Fund (IRISBF) matching grants for federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant recipients.  These firms have already received over $1.2 ...

Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A Dreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for ...

Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics Expert Rev. Clin. Pharmacol. 6(6), 651–662 (2013) Abstract Immune responses to some monoclonal antibodies (mAbs) and biologic proteins interfere with their efficacy due to the development of anti-drug antibodies (ADA). In the case of mAbs, most ADA target ‘foreign’ sequences present in the complementarity determining regions (CDRs). ...